We’re restoring the true meaning of healthcare—developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases. See how we're connecting the best of Health&Care for every patient and provider. https://lnkd.in/eW-mXA49
About us
At Johnson & Johnson Innovative Medicine, we are leading where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
- Website
-
https://www.janssen.com/johnson-johnson-innovative-medicine
External link for Johnson & Johnson Innovative Medicine
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Type
- Privately Held
Employees at Johnson & Johnson Innovative Medicine
Updates
-
At Johnson & Johnson, we’re excited about the power of #precisionmedicine to transform the future of #healthcare through the development and delivery of more personalized therapies for patients in need. Last week, we brought together hundreds of colleagues and external guest speakers for our third annual Global Precision Medicine Summit – an immersive, three-day experience where we discussed our efforts to help ensure the right medicines reach the right patients at the right time. Throughout the meeting, a few things were clear: ✅ There’s tremendous innovation in precision medicine today, powered by advancements in both science and technology ✅ Increased uptake of genetic and biomarker testing will be critical to deliver on the promise and potential of precision medicine ✅ Unprecedented collaboration – both internally and externally – will be needed to drive progress ✅ Johnson & Johnson is excited and ready to lead the way, keeping patients at the center of all we do Now that the summit has come to a close, our colleagues are feeling inspired, reinvigorated and energized by our efforts to bring innovative and tailored treatments to those who need them most. Learn more about our efforts in Precision Medicine: https://lnkd.in/gTSqQ_HB
-
There are an estimated 2.5 million #LungCancer diagnoses each year globally. Despite advancements in science, there is an urgent need for more treatment options for patients with this disease. That’s why we continue to build on our best-in-class lung cancer portfolio through the research and development of treatment options for #NSCLC. This #WorldLungCancerDay, we are working to make a difference for patients everywhere: https://bit.ly/4ft1w8E #InFrontofCancer #JNJOncology
-
With no treatments currently approved for X-linked retinitis pigmentosa (XLRP), those living with this disease face the inevitable deterioration of their sight. The American Journal of Ophthalmology recently published data from our Phase 1/2 study evaluating our gene therapy in patients with #XLRP. Learn how we are working to make a difference for these patients: https://lnkd.in/dDzyTDHE
-
#NEWS: Patients with transplant-eligible, newly diagnosed #MultipleMyeloma now have a new frontline quadruplet-based regimen. This approval is the latest example of how Johnson & Johnson is getting in front of cancer to improve patient outcomes and advance the standard of care for each line of treatment: https://lnkd.in/dtKbd3GR #JNJOncology
-
"We're committing the resources, the knowledge, the time to get in front of cancer.” John Eckardt, M.D., Oncology External Scientific Engagement Leader, Johnson & Johnson Innovative Medicine, knows that by working together, we can get #InFrontofCancer. By collaborating with scientific innovators, patient advocacy groups, and many others, we are better equipped to improve the lives of patients with cancer and ultimately drive to a cure: https://bit.ly/3Wpkzbm #WorldLungCancerDay #JNJOncology
-
This week, we’re at the Alzheimer's Association® International Conference (AAIC) to showcase our latest Alzheimer’s disease (AD) research, including findings that leverage advanced proteomics data sets and machine learning models. These scientific approaches, accompanied by our deep understanding of the complex pathology involved in this disease, lay the foundation for Johnson & Johnson's unique approach to tackling AD. Leading with a focus on precision, we’re relentlessly pursuing the development of therapies for patients and families affected by this complex disease. Learn more about our commitment to AD research and accelerating potential breakthroughs in this article from Bill Martin, PhD, Global Therapeutic Area Head, Neuroscience: https://bit.ly/3LC0OZ0 #AlzheimersDisease #AAIC24 #JNJNeuroscience
-
Today marks the 34th anniversary of the Americans with Disabilities Act (ADA), dedicated to ensuring people with disabilities are given equal rights and opportunities as their abled peers. Individuals in the low-vision community and others impacted by the ADA deserve accessible options in all areas of life but often experience barriers when it comes to accessing information digitally. To help support inclusivity and #Accessibilty, we’re sharing digital best practices to implement today and every day: https://bit.ly/46iLbiZ #ADA34
-
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for a new treatment for adult patients with #PulmonaryArterialHypertension (PAH). This significant milestone furthers our decades-long commitment to the PH community and fulfills our pledge to provide treatments that address all three foundational pathways for this progressive disease. Learn more here: https://bit.ly/4fljBp7 #JNJCardiopulmonary
-
Some dermatologic conditions can present differently across skin tones – leading to misdiagnoses or delays in treatment. Increasing diversity in the physician workforce is one way to help improve patient experiences and health outcomes. We’re proud to continue our collaboration with American Academy of Dermatology on Pathways: Inclusivity in Dermatology, a program that helps students from Black, Latino, and Indigenous communities learn more about careers in dermatology. This summer, we had the pleasure of meeting with 65 students in Chicago and Washington, D.C., and were inspired by their passion, engagement and interest in creating a more diverse future in #dermatology. Learn more: https://bit.ly/3WAqxYb